Hong, James S. W.
Ostinelli, Edoardo G.
Kamvar, Roya
Smith, Katharine A.
Walsh, Annabel E. L.
Kabir, Thomas
Tomlinson, Anneka
Cipriani, Andrea
Article History
Received: 8 March 2024
Accepted: 8 July 2024
First Online: 25 July 2024
Declarations
:
: The protocol for this project, titled ‘<i>Defining harms of antidepressants in depression: a free, online evidence-based dictionary of common adverse events that matter to patients and clinicians’</i>, was reviewed by the following Committee: Research Governance, Ethics and Assurance (RGEA) Team, University of Oxford, who confirmed that this project does not require ethical review or sponsorship by the University. Written and verbal informed consent to participate was obtained from all participants in the focus groups. Research was conducted in accordance with the Declaration of Helsinki.
: McPin consent forms were signed by members of the focus group who provided their age, gender and ethnicity data.
: JSWH, RK, KAS, AELW and TK declare no competing interests. AC has received research, educational and consultancy fees from INCiPiT (Italian Network for Paediatric Trials), CARIPLO Foundation, Lundbeck and Angelini Pharma; he is the CI/PI of one trial about seltorexant in adolescent depression, sponsored by Janssen. AT has received research, educational and consultancy fees from INCiPiT (Italian Network for Paediatric Trials), Angelini Pharma, Takeda and acted as a clinical advisor for Akrivia Health. EGO received research and consultancy fees from Angelini Pharma.